TY - JOUR
T1 - Prevention trials in Alzheimer's disease
T2 - An EU-US task force report
AU - Vellas, Bruno
AU - Aisen, Paul S.
AU - Sampaio, Cristina
AU - Carrillo, Maria
AU - Scheltens, Philip
AU - Scherrer, Bruno
AU - Frisoni, Giovanni B.
AU - Weiner, Michael
AU - Schneider, Lon
AU - Gauthier, Serge
AU - Wied, Christine C.Gispen de
AU - Hendrix, Suzanne
AU - Feldman, Howard
AU - Cedarbaum, Jesse
AU - Petersen, Ronald
AU - Siemers, Eric
AU - Andrieu, Sandrine
AU - Prvulovic, David
AU - Touchon, Jacques
AU - Hampel, Harald
N1 - Funding Information:
This work has been supported by the LOEWE excellence initiative Neuronal Coordination Research Focus Frankfurt (NeFF), Neurodegeneration Branch, Alzheimer's Disease Project, awarded to H.H. and D.P.
PY - 2011/12
Y1 - 2011/12
N2 - Despite enormous financial and scientific efforts, still no approved disease-modifying therapies exist for Alzheimer's disease (AD). During the last decade all Phase III clinical trials on disease modifiers in AD have failed. The dementia stage of AD being probably too late in order to allow for successful disease modification has been identified as a possible culprit that could explain the failure of so many clinical trials. In parallel, a major development in the diagnostic research field of AD was achieved by the recent proposal of new diagnostic criteria for AD, which also specifically incorporate the use of biomarkers as defining criteria for preclinical stages of AD, thus extending the traditional definition of disease to very early stages that may be a more feasible target for various disease modifying therapeutic interventions. This ongoing paradigm shift in AD definition and diagnosis represents a fundamental basis for redefinition of interventional trials in AD, allowing to specifically focus on preventative measures during very early pathophysiologically confirmed stages of disease. This consensus paper reflects the outcome from a European Union and North American Task Force meeting comprised of experts from academia, industry, private foundations, and regulatory agencies that was convened in Toulouse, France on November 5, 2010 and that focused on prevention trials in AD. This position paper thoroughly analyzes prerequisites for successful preventative trials in AD and concludes with concrete recommendations on biomarkers, statistical tools and other variables important for improved study designs suitable for preventative as well as for early therapeutic interventional trials in AD.
AB - Despite enormous financial and scientific efforts, still no approved disease-modifying therapies exist for Alzheimer's disease (AD). During the last decade all Phase III clinical trials on disease modifiers in AD have failed. The dementia stage of AD being probably too late in order to allow for successful disease modification has been identified as a possible culprit that could explain the failure of so many clinical trials. In parallel, a major development in the diagnostic research field of AD was achieved by the recent proposal of new diagnostic criteria for AD, which also specifically incorporate the use of biomarkers as defining criteria for preclinical stages of AD, thus extending the traditional definition of disease to very early stages that may be a more feasible target for various disease modifying therapeutic interventions. This ongoing paradigm shift in AD definition and diagnosis represents a fundamental basis for redefinition of interventional trials in AD, allowing to specifically focus on preventative measures during very early pathophysiologically confirmed stages of disease. This consensus paper reflects the outcome from a European Union and North American Task Force meeting comprised of experts from academia, industry, private foundations, and regulatory agencies that was convened in Toulouse, France on November 5, 2010 and that focused on prevention trials in AD. This position paper thoroughly analyzes prerequisites for successful preventative trials in AD and concludes with concrete recommendations on biomarkers, statistical tools and other variables important for improved study designs suitable for preventative as well as for early therapeutic interventional trials in AD.
KW - Alzheimer's disease
KW - Biomarkers
KW - Early intervention trials
KW - Prevention trials
KW - Study design
KW - Study planning
UR - http://www.scopus.com/inward/record.url?scp=82755189703&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=82755189703&partnerID=8YFLogxK
U2 - 10.1016/j.pneurobio.2011.08.014
DO - 10.1016/j.pneurobio.2011.08.014
M3 - Review article
C2 - 21925234
AN - SCOPUS:82755189703
SN - 0301-0082
VL - 95
SP - 594
EP - 600
JO - Progress in Neurobiology
JF - Progress in Neurobiology
IS - 4
ER -